Metraipolis › archive › dc_b294c8cec2d9
Evaluating the safety and feasibility of prophylactic third-party NK cell administration in high-risk AML patients post-HSCT — Europe PMC PMID:41275123
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41275123
- DOI
- 10.1186/s12885-[numero omesso]-8
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T08:15:54.416Z
- SHA-256 of the archived text
b5d193e0299c7cdab3a6d6569b260db352f6889b51602e2e7f63ca1348f38d31- Stable URL of this page
https://metraipolis.com/documento/dc_b294c8cec2d9
How to cite
Evaluating the safety and feasibility of prophylactic third-party NK cell administration in high-risk AML patients post-HSCT — Europe PMC PMID:41275123 — Europe PMC (en), https://europepmc.org/article/MED/41275123 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b294c8cec2d9 (Metraipolis archive dc_b294c8cec2d9, sha256 b5d193e0299c7cdab3a6d6569b260db352f6889b51602e2e7f63ca1348f38d31)
BibTeX
@misc{dcb294c8cec2d9,
title = {Evaluating the safety and feasibility of prophylactic third-party NK cell administration in high-risk AML patients post-HSCT — Europe PMC PMID:41275123},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41275123},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b294c8cec2d9; sha256 b5d193e0299c7cdab3a6d6569b260db352f6889b51602e2e7f63ca1348f38d31},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41275123. Agents can read the archived copy with the MCP tool read_document.